The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I'd like this company to get there, but the narrative that Draper has learned his lesson (this time) is off base. Aside from the management missteps that can be inferred from the company RNS and financials (why wait until the stock price had fallen to 3p before raising cash--that's a rhetorical question as the answer is clear), it was a seven months since he had a quick word with a tip sheet about the performance of the company (that caused the stock price to spike to 13p.
Moreover, the idea that this board has reined-in his behavior would have more credibility if the board was a stable presence not a revolving door. (That noted, the longer that Donald Stewart remains in place the greater the chance that corporate governance becomes a real foundation for the company.)
However, all this is noise. The real issue is ad rates, revenues and the move to profits. The longer the company takes to even match the success of November/ December last year, the greater the discrepancy between the valuation and the opportunity. In other words, if Bidstack makes its numbers (¢4m according to the Cenkos report) this year, it is currently trading at more than 5x revenues which would result in a loss of £6.3m. If the stock increases to, say 3p, it will be trading at 7x revenues. (Then consider the impact of any warrant dilution.)
That's troubling enough but ad rates show no signs at all of allowing the company to reach that goal and, if it doesn't, it will push the cash break even out way beyond 2022 and increase the amount of money that BIDS will need to raise next time.
viable: There is a good summary of the name on the Vox Podcast dated June 28--an interview by Paul Hill with Chris Mills (of Harwood Capital). (TRX features for 5 minutes from 16 minutes.)
https://audioboom.com/posts/7894897-vox-markets-fund-manager-interview-with-chris-mills
If you're not familiar with Vox, it's worth your time to the extent that it will introduce you to new companies. That noted it can be very promotional, especially with stocks that are owned by Justin Waite.
I've got a half position in the stock, so I'm no neutral, but I thought Cliff did a decent job of detailing the state of play. (I doubt he could release new info on a forum like that.) Given my druthers, I'd like the share price to come in again but in the short term it will be a proxy for BELL. All-in-all, an encouraging pitch by a competent manager.
That's not gonna happen any time soon. They might be able to get a pink sheet listing but they have a US broker (Stifel) in place for months and still had to get a UK raise through (Cenkos) and still had to offer a 30% discount to the already much decimated share price. Management isn't trusted at all. They're still not fully funded. Have recently changed focus away from AAA games to (smaller margin) mobile. They show no signs that their ad fill rates are stabilizing since the declines from the decent (non-programatic) rates before the end of last year. Other than that, etc....
Many thanks for these. A solid write-up by ST so encouraging. That noted, they're a little old so I'm trying to get a sense of whether to over-subscribe to the name ahead of the trading update. I still have little insight other than the banking sector returning to work (haven't found anyone new with direct client exposure to the software).
I’m having near zero success in doing background checks into the performance of the software—ease of use, popularity, etc. (A couple of people I’ve spoken with have noted that the operations in large banks are showing signs of life—staff returning to work in numbers, etc.)
Have you fellas had any luck tracking down users, etc?
borrowfundsfrommummy: Am not a holder and i've no idea if one can short this thing but not am I short. The numbers look ok, good sector, balance sheet in good shape, etc, cash flow not good but it a small AIM company and growing into its numbers. It has a backbone simulation division that accounts for the bulk of its revs and a new clinical AI division that, if you buy into the concept, is prob what's gonna grow this company. It that a fair summation or am i missing something?
Thanks in hope for a poke in the right direction.
"profit taking"... it was ever thus. Increasingly, it a business with excellent prospects (nuclear and biological threat detection, medical imaging, etc) and a CEO that is becoming more of a CEO than a PhD/ scientist.
If you're a trader, trade it. If you're an investor, stick it in the old oak chest and enjoy life.
jackdee1875
If you're new to investing, please don't over expose to this or any other investment. To educate yourself, listen to some of the recent podcasts of the TwinPetes, dip into twitter, etc. This I write not because I'm not a believer in MOS (I own a bunch of shares and am full of enthusiasm for the future) but any stock can go pear-shaped. Check the boards of BIDS, for an insight into what can go wrong and the vitriol it can generate.
Good luck to you, etc.
BlahBlahDoh... not nervous, or not very nervous, otherwise i would have sold down to zero. (I sliced my holdings a month ago so I'm long since in profit in the name regardless of what happens.) It's more a question of capital maintenance that any investor should ask of all of their holdings. ORPH is a £241m market cap that has performed astonishingly well and has excellent prospects for the future but we've not seen anything in terms of numbers for 9 months.
I'm not stirring--am a shareholder of long standing. Asking because it's a reasonable question.
Any of you fellas getting nervous about results—unless I missed something, I was September when they last published anything concrete?
In the US, for a week, and downtown Boston, New York and presumably surrounding areas are showing excellent on-going buildout of 5G. I've no insight on the q of MWE in this mix, but the sector is showing great expansion in the above cities.
I've at the initial stages of researching the company so before i commit a full week of research.... this looks like an £18m with too many product lines for a zero revenue company. What am i missing? (I hope the above doesn't read too aggressive.)
Interesting review of the quarter by Moni Borovitz on 'investor meet company', late last week. The professional/ consulting services and sales to the military had been a little problematic (Covid) but these headwinds are easing. All other operations looking good and revenue growth forecast high single/ low double digits with profits ahead of that.
I still cannot access the doc, but perhaps that is a fault on my end. I listened to the chat called-out by 'FreddyFIB 23', above, but it focused to large extent on TIZ. Cerrone discussed the shortened review time for OKYO treatments (vs. TIZ) but added little color. There was an acknowledgment that TIZ has fallen short of investor rels. in the past and they've now taken steps to address that so it would be interesting to see if, in future, there is an improved effort in this dept for OKYO. All that aside, I heard little nothing on the business side to encourage me to buy (either TIZ or OKYO) but the med tech still looks attractive.
I've been trying to bend my brain around this name for a couple of days, but haven't made any progress. Given the results (released March 28) and the colossal dilution (confirmed this week), is the value prop a combo of the tech, emergence from Covid, and evolving nature of advertising/ direct marketing? (It feels like management have been almost uniquely unlucky in the last year--Covid, fast changing approach of Apple, etc., to privacy issues--and under capitalized. In other words... what am i missing? (Sorry for the lazy questions, but I'm short of energy these days.)
Rokerpark68
Many thanks for your note. (My apologies for not seeing it before today.)
I've tried to access the doc through the Okyo site but it's not yet posted and the link they offered at
http:/data.fca.org/#nsm/nationalstoragemechanism
doesn't work. I'll confess that I'm short on patience today and very tired but will look again tomorrow.
Could I ask if you have a position in the name?
Kind regards, and the like.